NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA,
AUSTRALIA OR JAPAN
Announcement no. 6/2007
To the Copenhagen Stock Exchange and the press.
Copenhagen, 29 May 2007
Below are Exiqon A/S' planned dates for financial reporting the next 12 months:
Financial calendar
Interim report for the period 1 January - 30 June 2007: 28 August 2007
Interim report for the period 1 January - 30 September 2007: 27 November 2007
Announcement of full-year results 2007: 12 March 2008
The annual general meeting will be held on 28 March 2008.
For additional information please contact
Lars Kongsbak, CEO, tel +45 4566 0888 or +45 4090 2101
Hans Henrik Chrois Christensen, CFO +45 4565 0953 or +45 4090 2131
Exiqon is a biotechnology company engaged in the development, manufacture and
marketing of products for genetic analysis.
Exiqon is witnessing strong growth and is one of the innovative leaders in the
segments we have selected. We sell our products to a rapidly growing number of
scientists in the pharmaceutical industry and in research laboratories around
the world. These products include reagents and kits which in a precise and
sensitive manner translate the information in the genes into the answers sought
by the scientists and the industry.
Exiqon's products build on the company's patented Locked Nucleic Acid (LNA™)
technology. We expect to further develop our existing products and technologies
so that we can deliver future solutions to important challenges in the field of
molecular diagnostics.
Exiqon's products are marketed through its own sales organisation and trough
license and distribution agreements with recognised partners, including Roche
Diagnostics and Luminex